Skip to main content

Zymeworks Inc.

corporate_fare Company Profile

Zymeworks Inc.

ZYME·NASDAQ·Life Sciences·CIK 0001937653

Zymeworks is a global biotechnology company that manages a portfolio of licensed healthcare assets and develops new, multifunctional biotherapeutics. These biotherapeutics aim to improve treatment for difficult conditions such as cancer, inflammation, and autoimmune disease. The company's strategy focuses on increasing stockholder value through royalty growth, strategic acquisitions, and internal innovation. This is supported by disciplined capital allocation and a stronger financial foundation from expected milestone payments and royalties from existing commercial partners. Zymeworks discovers or acquires and develops a diversified portfolio of preclinical or clinical healthcare assets. It also evaluates strategic partnership opportunities to transfer certain costs and risks related to clinical development and/or commercialization to partners, securing the right to receive potential future royalty and milestone revenues. The company uses its expertise in protein engineering and drug chemistry to discover and develop next-generation antibody-based therapeutics for significant unmet medical needs, especially in hard-to-treat diseases. Its proprietary structure-guided molecular modeling, combined with internal antibody discovery and generation technologies, supports a fully integrated drug development engine. Zymeworks' pipeline of multifunctional therapeutics is supported by its multispecific antibody therapeutics ("MSATs") and antibody-drug conjugates ("ADCs") technology platforms, which enable the development of novel therapeutics in cancer, inflammation, and autoimmune disease and create opportunities for new partnerships. Partnerships and collaborations are a key part of its strategy, serving as a potential source of funding for ongoing research and development and reducing reliance on internal capital for later-stage clinical development of partnered assets.

Zymeworks Inc. (NASDAQ:ZYME) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ZYME at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Zymeworks Appoints Kristin Stafford as Executive VP & CFO, Strengthening Financial Leadership
  • FDA Grants Fast Track to Zymeworks' ZW191 for Ovarian Cancer, Accelerating Development
  • Zymeworks Secures $250M Non-Recourse Royalty Financing from Royalty Pharma, Extends Cash Runway
  • Zymeworks Secures $250M Non-Dilutive Financing, Reports Strong 2025 Results, and Advances Key Pipeline Assets
  • Zymeworks Reports Strong FY25 Results, Secures $250M Non-Dilutive Financing, and Advances Lead Asset Towards US Launch

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$105.97M
Net Income
-$81.13M
Diluted EPS
-$1.08
Op. Cash Flow
-$33.01M
Free Cash Flow
-$34.53M
Operating Income
-$92.55M
Cash & Equivalents
$41.16M
Debt / Equity
0.00×
Net Margin
-76.6%
Shares Outstanding
74.64M sh
Source: 10-K · filed 2026-03-02 · accession 0001937653-26-000015
$26.14
52-week range · as of 2026-11-09 $16 – $31.49
Market cap
$1.81B
Volume
738.8K (0.6× avg)
3-mo avg 1.3M
Live data · 2026-11-22 12:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZYME - Filings & News (Page 2)

ZYME
Apr 01, 2026, 6:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $24.99
Real-time Price: $26.14 info
Change: +$1.15 (+5%) info
Market Cap: $1.81B info
ZYME
Mar 30, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $24.90
Real-time Price: $26.14 info
Change: +$1.24 (+5%) info
Market Cap: $1.81B info
ZYME
Mar 02, 2026, 6:28 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $23.40
Real-time Price: $26.14 info
Change: +$2.74 (+12%) info
Market Cap: $1.81B info
ZYME
Mar 02, 2026, 6:28 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $23.40
Real-time Price: $26.14 info
Change: +$2.74 (+12%) info
Market Cap: $1.81B info
ZYME
Mar 02, 2026, 6:03 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $23.40
Real-time Price: $26.14 info
Change: +$2.74 (+12%) info
Market Cap: $1.81B info
ZYME
Mar 02, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $23.40
Real-time Price: $26.14 info
Change: +$2.74 (+12%) info
Market Cap: $1.81B info
ZYME
Jan 12, 2026, 4:34 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $23.16
Real-time Price: $26.14 info
Change: +$2.98 (+13%) info
Market Cap: $1.81B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets